NCT04093167View on ClinicalTrials.gov

Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

May 26, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

July 30, 2027

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Pembrolizumab

Per current Product Monograph/U.S. Drug Label and/or local guidelines.

Trial Locations (6)

21231

RECRUITING

The Sidney Kimmel Comprehensive Cancer Centre, Baltimore

V5Z 4E6

RECRUITING

BCCA - Vancouver Cancer Centre, Vancouver

L8V 5C2

RECRUITING

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 2V7

RECRUITING

Kingston Health Sciences Centre, Kingston

K1H 8L6

RECRUITING

Ottawa Hospital Research Institute, Ottawa

M5G 2M9

RECRUITING

University Health Network, Toronto

Sponsors
All Listed Sponsors
collaborator

Cancer Research Institute, New York City

OTHER

collaborator

Personal Genome Diagnostics

INDUSTRY

collaborator

Mark Foundation for Cancer Research

UNKNOWN

lead

Canadian Cancer Trials Group

NETWORK